Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?

International Journal of Clinical Practice

Volumn 68, Issue 9, 2014, Pages 1165-1173

  Gibson, W ^a   Athanasopoulos, A ^b   Goldman, H ^c   Madersbacher, H ^d   Newman, D ^e   Spinks, J ^f   Wyndaele, J J ^g   Wagg, A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF PATRAS   (Greece)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f Court View Surgery ^*  (United Kingdom)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; BENZHYDRYL DERIVATIVE; CRESOL; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENYLPROPANOLAMINE;

COST BENEFIT ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FRAIL ELDERLY; GERIATRIC CARE; HUMAN; NONHUMAN; OVERACTIVE BLADDER; PHARMACEUTICAL CARE; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; URGE INCONTINENCE; AGED; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CHOLINERGIC ANTAGONISTS; CRESOLS; FRAIL ELDERLY; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84908110214     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12447     Document Type: Review

References (86)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21(2): 167-78.
2. Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/ International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29(1): 4-20.
3. Wyndaele JJ, Van Meel TD, De Wachter S. Detrusor overactivity. Does it represent a difference if patients feel the involuntary contractions? J Urol, 2004; 1: 1915-8.
4. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 2003; 92(4): 415-7.
5. Wagg AS. Antimuscarinic treatment in overactive bladder: special considerations in elderly patients. Drugs Aging 2012; 29(7): 539-48.
6. Irwin DE, Milsom I, Hunskaar S et al. Population- based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50(6): 1306-14; discussion 1314-5.
7. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S; Norwegian EPINCONT study; Epidemiology of Incontinence in the County of Nord-Trøndelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000; 53(11): 1150-7.
8. Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990; 66(5): 479-85.
9. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006 4(4): CD003781.
10. Thompson IM, Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology 1976; 8(5): 452-4.
11. Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20(3): 307-14.
12. Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012; 1: CD005429.
13. Baigrie RJ, Kelleher JP, Fawcett DP, Pengelly AW. Oxybutynin: is it safe? Br J Urol 1988; 62(4): 319-22.
14. Riva D, Casolati E. Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol 1984; 11(1-2): 37-42.
15. Thuroff JW, Bunke B, Ebner A et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145(4): 813-6; discussion 816-7.
16. Tapp AJ, Cardozo LD, Versi E, Cooper D. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97(6): 521-6.
17. Gallagher P, O'Mahony D. Constipation in old age. Best Pract Res Clin Gastroenterol 2009; 23(6): 875-87.
18. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012; 110(11): 1767-74.
19. Primus G, Pummer K. Oxybutynin hydrochloride in the management of detrusor instability. Int Urol Nephrol 1990; 22(3): 243-8.
20. Kay GG, Abou-Donia MB, Messer WS Jr et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005; 53(12): 2195-201.
21. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005; 27(2): 144-53.
22. Popescu BO, Toescu EC, Popescu LM et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 2009; 283(1-2): 99-106.
23. Yoshida A, Maruyama S, Fukumoto D et al. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sci 2010; 87(5-6): 175-80.
24. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47(4): 337-43.
25. Yamamoto S, Maruyama S, Ito Y et al. Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB. Neuroimage 2011; 58(1): 1-9.
26. Katz IR, Sands LP, Bilker W et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46(1): 8-13.
27. Staskin D, Kay G, Tannenbaum C et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010; 64(9): 1294-300.
28. Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double- blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013; 64(1): 74-81.
29. Kay GG, Maruff P, Scholfield D et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad Med 2012; 124(3): 7-15.
30. Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50(2): 317-26.
31. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008; 62(11): 1792-800.
32. Sink KM, Thomas J 3rd, Xu H et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008; 56(5): 847-53.
33. Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc 2011; 59(7): 1332-9.
34. Sand P, Zinner N, Newman D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community- based, randomized study. BJU Int 2007; 99 (4): 836-44.
35. Goldfischer ER, Sand PK, Thomas H, Peters-Gee J. Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn 2013; ePub ahead of print, doi: 10.1002/nau.22504
36. Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J 2013; 24(4): 595-604.
37. Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol 2007; 51(4): 907-14; discussion 914.
38. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002; 18(4): 177-84.
39. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled- release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000; 95(5): 718-21.
40. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005; 23(4): 248-52.
41. Zinner NR. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother 2005; 6(8): 1409-20.
42. McMurdo ME, Roberts H, Parker S et al. Improving recruitment of older people to research through good practice. Age Ageing 2011; 40(6): 659-65.
43. Rockwood K, Song X, MacKnight C et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173(5): 489-95.
44. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146-56.
45. Irwin DE, Milsom I, Chancellor MB, Kopp Z, Guan Z. Dynamic progression of overactive bladder and urinary incontinence symptoms: a systematic review. Eur Urol 2010; 58(4): 532-43.
46. Meek PD, Evang SD, Tadrous M et al. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011; 56(1): 7-18.
47. Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012; 62(6): 1040-60.
48. Kessler TM, Bachmann LM, Minder C et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS ONE 2011; 6(2): e16718.
49. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60 (4): 616-31.
50. Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008; 37(6): 673-9.
51. Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 2010; 107(31-32): 543-51.
52. CG171 urinary incontinence in women, 2013. http://guidance.nice.org.uk/CG171/NICEGuidance/ pdf/English (accessed 1st November 2013).
53. McDonagh MS, Selover D, Santa J, Thakurta S. Drug class review: agents for overactive bladder. Final Report Update 4. Portland, OR, 2009.
54. Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76(4): 358-63.
55. Homma Y, Paick JS, Lee JG et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003; 92(7): 741-7.
56. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81(6): 801-10.
57. Lee JG, Hong JY, Choo MS et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 2002; 9(5): 247-52.
58. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20(6): 392-9.
59. Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78(6): 687-95.
60. Madersbacher H, Stohrer M, Richter R et al. Trospium chloride versus oxybutynin: a randomized, double- blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995; 75(4): 452-6.
61. Bemelmans BL, Kiemeney LA, Debruyne FM. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects. Eur Urol 2000; 37(6): 709-13.
62. Burton G. A randomised cross over trial comparing oxybutynin taken three times a day or taken 'when needed'. Neurourol Urodyn 1994; 13: 2.
63. Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995; 24(4): 287-91.
64. Nitz NM, Jumadilova Z, Darkow T, Frytak JR, Bavendam T. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Am J Manag Care 2005; 11 (4 Suppl): S130-9.
65. Herschorn S, Vicente C, Piwko C. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. J Med Econ 2010; 13(3): 508-15.
66. Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Investig 2004; 24(6): 305-21.
67. Nilsson FO, Linner L, Samuelsson E, Milsom I. Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. BJU Int 2012; 110 (2): 240-6.
68. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48(1): 5-26.
69. Cardozo L, Thorpe A, Warner J, Sidhu M. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate- release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int 2010; 106(4): 506-14.
70. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005; 11(4 Suppl): S140-9.
71. Colling J, Owen TR, McCreedy M, Newman D. The effects of a continence program on frail community- dwelling elderly persons. Urol Nurs 2003; 23(2): 117-22, 127-31.
72. Subak LL, Brown JS, Kraus SR et al. The "costs" of urinary incontinence for women. Obstet Gynecol 2006; 107(4): 908-16.
73. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005; 11(4 Suppl): S121-9.
74. Staskin DR, Chawla RK, Oefelein MG. Pharmacodynamics of overactive bladder drugs: shifting the curve. Curr Bladder Dysfunct Rep 2011; 6(1): 13.
75. Callegari E, Malhotra B, Bungay PJ et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72(2): 235-46.
76. Kay GG, Staskin DR, MacDiarmid S, McIlwain M, Dahl NV. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clin Drug Investig 2012; 32(10): 707-14.
77. Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin 2012; 28(8): 1369-79.
78. Yoo DS, Han JY, Lee KS, Choo MS. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. Int J Clin Pract 2012; 66(2): 132-8.
79. Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56(5): 862-70.
80. Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. J Am Med Dir Assoc 2011; 12(9): 639-47.
81. Herschorn S, Pommerville P, Stothers L et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (<= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double- blind study. Curr Med Res Opin 2011; 27(2): 375-82.
82. Minassian VA, Ross S, Sumabat O et al. Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial. J Obstet Gynaecol Can 2007; 29(9): 726-32.
83. Johnson TM 2nd, Burgio KL, Redden DT, Wright KC, Goode PS. Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005; 53(5): 846-50.
84. Goode PS, Burgio KL, Locher JL et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc 2002; 50(5): 808-16.
85. Ouslander JG, Schnelle JF, Uman G et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995; 43(6): 610-7.
86. Zorzitto ML, Holliday PJ, Jewett MA, Herschorn S, Fernie GR. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 1989; 18(3): 195-200.